Scholarlink

Objective <p>To present the clinical course and outcome of a patient with advanced hepatocellular carcinoma (HCC) who received HBsAg-targeted T cell receptor-engineered T cells (TCR-T).</p> Case presentation <p>A 61-year-old man with advanced HCC developed cytokine release syndrome (CRS) after HBsAg-targeted TCR-T infusion, which met grade 3 criteria within 24 h and then rapidly improved to grade 2, alleviated after two weeks. Although hematologic toxicities were prominent, recovery was achieved and there were no severe consequences. At 6 weeks post-infusion, the patient's cervical lymph nodes and pulmonary metastases showed slight reduction, suggesting a possible transient therapeutic effect. However, by day 87 post-infusion, all lesions had progressed again. Meanwhile, the bone metastases demonstrated continuous progression.</p> Conclusion <p>HBsAg-targeted TCR-T cell therapy may represent a potential therapeutic strategy for advanced HCC, demonstrating a manageable safety profile when carefully monitored for ≥ Grade 3 cytokine release syndrome and hematological toxicities.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Treatment of advanced hepatocellular carcinoma with HBsAg-targeted TCR engineered -T Cells: a case report

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月23日

查看全文
  • Sidi Wei,
  • Lan Gu,
  • Jieyi Shi,
  • Wenwen Wang

摘要

Objective

To present the clinical course and outcome of a patient with advanced hepatocellular carcinoma (HCC) who received HBsAg-targeted T cell receptor-engineered T cells (TCR-T).

Case presentation

A 61-year-old man with advanced HCC developed cytokine release syndrome (CRS) after HBsAg-targeted TCR-T infusion, which met grade 3 criteria within 24 h and then rapidly improved to grade 2, alleviated after two weeks. Although hematologic toxicities were prominent, recovery was achieved and there were no severe consequences. At 6 weeks post-infusion, the patient's cervical lymph nodes and pulmonary metastases showed slight reduction, suggesting a possible transient therapeutic effect. However, by day 87 post-infusion, all lesions had progressed again. Meanwhile, the bone metastases demonstrated continuous progression.

Conclusion

HBsAg-targeted TCR-T cell therapy may represent a potential therapeutic strategy for advanced HCC, demonstrating a manageable safety profile when carefully monitored for ≥ Grade 3 cytokine release syndrome and hematological toxicities.